BDR Pharmaceuticals has signed a contract-manufacturing deal with Cipla for remdesivir, a patented product of US company Gilead Sciences.
Earlier, The Mumbai-based company had sought the s approval of India’s drug regulator to make and sell remdesivir in India without entering into an arrangement with Gilead.
Now BDR has signed a contract to make the drug for Cipla, which is one of the licensed companies.
Gilead has signed voluntary licensing agreements with Cipla, Hetero Labs and Jubilant Life Sciences for the manufacture and sale of remdesivir in 127 poor and middle-income nations including India.
Dharmesh Shah, MD of BDR said, “Nothing is more important than accessibility and affordability for Covid-19 patients and if remdesivir is working, it should be available soon”
However, It is still not known if Gilead has permitted its licensees to enter into sub-licensing manufacturing contracts.
